Latest Biotechnology Sector News

CSL Limited has updated its dividend announcement for the first half of FY2025, confirming a USD 1.62 per share ordinary dividend and clarifying currency payment arrangements for global shareholders.

Mesoblast has entered agreements to issue up to US$50 million in convertible notes, aiming to strengthen its capital base and support pipeline growth, pending shareholder approval.

Rhythm Biosciences has significantly reduced its annual loss by 44%, boosted by a 91% rise in other income, while launching a new wholly owned subsidiary, RHY GeneType Pty Ltd.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Opthea has successfully settled its Development Funding Agreement, avoiding a potential $680 million liability and securing $20 million in cash. Leadership changes include the CEO and CFO stepping down, with the Chairman assuming CEO duties.

CSL Limited has announced an unfranked ordinary dividend of USD 1.62 per share for the first half of 2025, with payments scheduled in multiple currencies depending on shareholder location.

Invion Limited’s IVXO securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing and investor confidence.

Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.

Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.

Wide Open Agriculture Limited reminds shareholders of the imminent closing of its Securities Purchase Plan, offering shares at a discounted price with free options, while gearing up for an investor webinar to discuss company progress.